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ABSTRACT
Prediction and elucidation of pharmacogenetic
effects is important for facilitating the develop-
ment of personalized medicines. Knowledge of
polymorphism-induced and other types of drug-
response variations is needed for facilitating such
studies. Although databases of pharmacogenetic
knowledge, polymorphism and toxicogenomic
information have appeared, some of the relevant
data are provided in separate web-pages and in
terms of relatively long descriptions quoted from
literatures. To facilitate easy and quick assessment
of the relevant information, it is helpful to develop
databases that provide all of the information related
to a pharmacogenetic effect in the same web-page
and in brief descriptions. We developed a database,
Pharmacogenetic Effect Database (PharmGED), for
providing sequence, function, polymorphism, affec-
ted drugs and pharmacogenetic effects. PharmGED
can be accessed at http://bidd.cz3.nus.edu.sg/phg/
free of charge for academic use. It currently con-
tains 1825 entries covering 108 disease conditions,
266 distinct proteins, 693 polymorphisms, 414
drugs/ligands cited from 856 references.
INTRODUCTION
Individual response to drugs often differs signiﬁcantly and
these drug-response variations are frequently associated
with polymorphisms of pharmacologically related proteins
(1–5). Pharmacogenetic study of these proteins and their
regulatory sites is important for the understanding of molecu-
lar mechanism of drug responses and for the development of
personalized medicines (1,6–9). Resources that provide
information about molecular mechanism of drug-response
variations are useful for facilitating pharmacogenomics
study and the development of personalized medicine (10).
There have been calls and efforts for developing such
resources (11) and the related informatics tools (12,13). A
number of freely accessible web-based resources have been
developed for providing information about genetic and
clinical pharmacogenetic information (14), polymorphisms in
drug-related proteins (15–20) and toxicogenomics data (21).
Although pharmacogenetic knowledge, polymorphism and
toxicogenomic information are provided in these databases,
some of the reported pharmacogetic effects are given in
web-pages separate from that of other important information
such as protein and drug information, and are often given by
relatively long descriptions quoted from literatures. To facili-
tate easy and quick assessment of the relevant information, it
is helpful to develop databases that provide all the infor-
mation related to a pharmacogenetic effect in the same
web-page. We developed Pharmacogenetic Effect Database
(PharmGED) with the aim to provide the information about
the effects of a particular protein polymorphism, non-coding
region mutation, splicing alteration or expression variation
on the response of a particular drug. It currently contains
1825 entries covering 108 disease conditions, 266 distinct
proteins, 693 polymorphisms, 414 drugs/ligands cited from
856 references.
DATABASE STRUCTURE AND ACCESS
PharmGED has a web interface at http://bidd.cz3.nus.edu.sg/
phg/. The entries of this database were derived from a com-
prehensive search of published literatures (via Medline) by
using a similar search and evaluation procedure as we have
used for developing other databases of drug-related proteins
(15–18). Entries of this database are searchable by several
methods. These methods include the search of protein
name, drug/ligand name, disease name (extracted from the
related terms described in the relevant publications) and
drug class (derived based on the related terms described in
the relevant publications). Full list of protein names, drug/
ligand names, disease names and drug classes are separately
provided in the PharmGED main web-page for facilitating the
search of particular entries.
Moreover, keyword-based text search is also supported.
The search is case insensitive and wildcards are supported.
In a query, a user can specify full name or any part of the
name in a text ﬁeld. Wild character of ‘*’ and ‘?’ is allowed
in text ﬁeld. Here, ‘?’ represents any single character
*To whom correspondence should be addressed. Tel: +65 6516 6877; Fax: +65 6774 6756; Email: phacyz@nus.edu.sg
  2006 The Author(s).
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
D794–D799 Nucleic Acids Research, 2007, Vol. 35, Database issue Published online 6 December 2006
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example, input of ‘dehydrogenase’ in the ﬁeld of protein/
gene name enables the ﬁnding of all entries containing ‘dehy-
drogenase’ in the protein name, such as 3-oxo-5-alpha-steroid
4-dehydrogenase 2, Alcohol dehydrogenase 1B, Alcohol
dehydrogenase 1C, Fatty aldehyde dehydrogenase, Glucose-
6-phosphate 1-dehydrogenase, NAD(P)H dehydrogenase
(quinone) 1, etc. On the other hand, input of Fatty*
dehydrogenase enables the ﬁnding of all dehydrogenases
whose names start with ‘Fatty’.
The result of a typical search is illustrated in Figure 1. In
this interface, all entries that satisfy the speciﬁed search
criteria are listed along with protein name, polymorphism
rules, drug/ligand name, drug classiﬁcation, disease name
Figure 1. The interface displaying a search result on PharmGED. All entries that satisfy the specified search criteria are listed along with protein name,
polymorphism rules, drug/ligand name, drug classification, disease name and links to other related entries in this database.
Nucleic Acids Research, 2007, Vol. 35, Database issue D795and links to other related entries in this database. More
detailed information of an entry can be obtained by clicking
the corresponding protein name. The result is displayed in an
interface shown in Figure 2. From this interface, one ﬁnds the
accession number, name, sequence and function of protein,
pharmacogenetic polymorphism, affected drugs and drug
class, corresponding disease condition and pharmacogenetic
effect. Moreover, the information about the related references
and links to the literature database PUBMED (22) is also
provided.
POTENTIAL APPLICATIONS
Established links between polymorphisms of drug-related pro-
teinsandindividualdrugresponseshavebeenusedincombina-
tion with genetic studies as indicators for predicting individual
variations of drug response (23–27). Based on the statistical
analysis of the data of polymorphisms and variation of drug
response of the participating patients, simple rules may be
derived in some cases for predicting individual variations of
drug response from polymorphism data (23,24,26,28,29).
These simple rules may be collected and used for developing
Figure 2. Interface displaying the detailed information of an entry in PharmGED.
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Nucleic Acids Research, 2007, Vol. 35, Database issue D797a computer prediction system in a fashion similar to that of the
HIV drug-resistant genotype interpretation systems (30).
Table 1 gives examples of the drug-related proteins in
PharmGED with available information about pharmacoge-
netic polymorphism and drug-response variation from
which a reasonably accurate rule have been derived in the lit-
erature for predicting responses to a speciﬁc drug or drug
group. The reported percentage of patients who have a poly-
morphism and showed the expected effect is also given.
Based on the test of the patients described in these reports,
most of these rules are capable of predicting drug responses
at success rates of 50–100%, which are not too much lower
than and in many cases comparable to the accuracies of
81–97% for predicting HIV drug resistance mutations from
the HIV-resistant genotype interpretation systems (30). This
suggests that these simple rules have certain level of capacity
for facilitating the prediction of pharmacogenetic effects
and they may be used as the basis for developing more
sophisticated interpretation systems similar to those of the
HIV-resistant genotype interpretation systems (30).
PharmGED and other databases (14–21) can be potentially
used for facilitating the generation of these rules. For instance,
one entry of PharmGED describes that patients using classical
neuropleptic such as ﬂuphenazine, haloperidol have a higher
incidence (81%) of Tardive dyskinesia if they are of the
genotype CYP2D6*4. The corresponding polymorphism can
be obtained from a link provided in the database. These data
combined with other information in PharmaGED can be used
to generate the rule for detecting this pharmacogenetic effect
described in Table 1. In a second example, another entry of
PharmGED describes that the polymorphism C3435T
(Ile1145Ile) of protein MDR1-3435 variant is associated with
different virologic response of nelﬁnavir in HIV-1 infected
children. Fifty-nine percent of the 31 C/C genotype and 91%
of the 33 C/T genotype show virologic response at eighth
week, respectively. These data can then be used to generate
the rule for this pharmacogenetic effect as described in Table 1.
CONCLUDING REMARKS
Knowledge about protein polymorphisms and drug responses
appears to have reached a meaningful level for facilitating
pharmacogenetic study and for predicting various types of
individual variations of drug responses. Specialized pharma-
cogenetics databases serve as convenient resources for
obtaining the relevant information. With the rapid develop-
ment of genomics (31), pharmacokinetics (32–35) and phar-
macogenomics (6,8,9), more information about drug-related
proteins, polymorphisms and variations of drug responses
are expected to become available. Moreover, progress in
the study of proteomics (36) and pathways (37) related to
drug-related proteins will further facilitate our understanding
of the mechanism of individual variations in drug response.
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